The DOI matches its Crossref record; 170 of the 170 references it cites were found in a registry or an index.
The PI3K/Akt Pathway and Glucose Metabolism: A Dangerous Liaison in Cancer
Open accessAbstract
Aberrant activation of the PI3K/Akt pathway commonly occurs in cancers and correlates with multiple aspects of malignant progression. In particular, recent evidence suggests that the PI3K/Akt signaling plays a fundamental role in promoting the so-called aerobic glycolysis or Warburg effect, by phosphorylating different nutrient transporters and metabolic enzymes, such as GLUT1, HK2, PFKB3/4 and PKM2, and by regulating various molecular networks and proteins, including mTORC1, GSK3, FOXO transcription factors, MYC and HIF-1α. This leads to a profound reprogramming of cancer metabolism, also impacting on pentose phosphate pathway, mitochondrial oxidative phosphorylation, de novo lipid synthesis and redox homeostasis and thereby allowing the fulfillment of both the catabolic and anabolic demands of tumor cells. The present review discusses the interactions between the PI3K/Akt cascade and its metabolic targets, focusing on their possible therapeutic implications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
3 retracted
Csibi, A., Lee, G., Yoon, S.-O., Tong, H., Ilter, D., Elia, I., Fendt, S.-M., Roberts, T. M., & Blenis, J. (2014) · Current Biology · doi:10.1016/j.cub.2014.08.007 · Cited by 256
RetractedRETRACTED: SLC1A3 promotes gastric cancer progression via the PI3K/AKT signalling pathway
Xu, L., Chen, J., Jia, L., Chen, X., Moumin, F. A., & Cai, J. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.16060 · Cited by 62
RetractedHe, R. Q., & Liu, H. (2020) · Gene · doi:10.1016/j.gene.2020.144553 · Cited by 37
RetractedUnderstanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
Vander Heiden, M. G., Cantley, L. C., & Thompson, C. B. (2009) · Science · doi:10.1126/science.1160809 · Cited by 16,197
The Warburg Effect: How Does it Benefit Cancer Cells?
Liberti, M. V., & Locasale, J. W. (2016) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2015.12.001 · Cited by 5,150
Otto Warburg's contributions to current concepts of cancer metabolism
Koppenol, W. H., Bounds, P. L., & Dang, C. V. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3038 · Cited by 3,427
Aerobic glycolysis: Meeting the metabolic requirements of cell proliferation
Lunt, S. Y., & Vander Heiden, M. G. (2011) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev-cellbio-092910-154237 · Cited by 3,057
Exploiting the PI3K/AKT Pathway for Cancer Drug Discovery
Hennessy, B. T., Smith, D. L., Ram, P. T., Lu, Y., & Mills, G. B. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1902 · Cited by 2,185
ROS in cancer therapy: the bright side of the moon
Perillo, B., Di Donato, M., Pezone, A., Di Zazzo, E., Giovannelli, P., Galasso, G., Castoria, G., & Migliaccio, A. (2020) · Experimental & Molecular Medicine · doi:10.1038/s12276-020-0384-2 · Cited by 2,176
The PI3K–AKT network at the interface of oncogenic signalling and cancer metabolism
Hoxhaj, G., & Manning, B. D. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-019-0216-7 · Cited by 2,137
The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy
Muz, B., de la Puente, P., Azab, F., & Azab, A. K. (2015) · Hypoxia · doi:10.2147/hp.s93413 · Cited by 2,066 · cited 1×
“A distinctive hallmark of several malignancies is that they develop in a hypoxic environment [115].”
BackgroundActivation of a metabolic gene regulatory network downstream of mTOR complex 1
Düvel, K., Yecies, J. L., Menon, S., Raman, P., Lipovsky, A. I., Souza, A. L., Triantafellow, E., Ma, Q., Gorski, R., Cleaver, S., et al. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.06.022 · Cited by 2,020
PI3K pathway alterations in cancer: variations on a theme
Yuan, T. L., & Cantley, L. C. (2008) · Oncogene · doi:10.1038/onc.2008.245 · Cited by 1,845
The multifaceted roles of fatty acid synthesis in cancer
Röhrig, F., & Schulze, A. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.89 · Cited by 1,651
Fantin, V. R., St-Pierre, J., & Leder, P. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.04.023 · Cited by 1,635
Targeting PI3K in cancer: mechanisms and advances in clinical trials
Yang, J., Nie, J., Ma, X., Wei, Y., Peng, Y., & Wei, X. (2019) · Molecular Cancer · doi:10.1186/s12943-019-0954-x · Cited by 1,520
(2000) · PubMed · Cited by 1,445
Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability
Sears, R., Nuckolls, F., Haura, E., Taya, Y., Tamai, K., & Nevins, J. R. (2000) · Genes & Development · doi:10.1101/gad.836800 · Cited by 1,393
Stine, Z. E., Walton, Z. E., Altman, B. J., Hsieh, A. L., & Dang, C. V. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0507 · Cited by 1,375
Cancer metabolism: fatty acid oxidation in the limelight
Carracedo, A., Cantley, L. C., & Pandolfi, P. P. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3483 · Cited by 1,324
The updated landscape of tumor microenvironment and drug repurposing
Jin, M.-Z., & Jin, W.-L. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00280-x · Cited by 1,262
Laughner, E., Taghavi, P., Chiles, K., Mahon, P. C., & Semenza, G. L. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.12.3995-4004.2001 · Cited by 1,256
Hudson, C. C., Liu, M., Chiang, G. G., Otterness, D. M., Loomis, D. C., Kaper, F., Giaccia, A. J., & Abraham, R. T. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.20.7004-7014.2002 · Cited by 1,186
Hemmings, B. A., & Restuccia, D. F. (2012) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a011189 · Cited by 1,049
Reactive Oxygen Species in Cancer: Current Findings and Future Directions
Nakamura, H., & Takada, K. (2021) · Cancer Science · doi:10.1111/cas.15068 · Cited by 1,027
Majumder, P. K., Febbo, P. G., Bikoff, R., Berger, R., Xue, Q., McMahon, L. M., Manola, J., Brugarolas, J., McDonnell, T. J., Golub, T. R., et al. (2004) · Nature Medicine · doi:10.1038/nm1052 · Cited by 964
Energy metabolism of cancer: Glycolysis versus oxidative phosphorylation (Review)
ZHENG, J. (2012) · Oncology Letters · doi:10.3892/ol.2012.928 · Cited by 963
Regulation of mammalian nucleotide metabolism and biosynthesis
Lane, A. N., & Fan, T. W.-M. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv047 · Cited by 959
Welcker, M., Orian, A., Jin, J., Grim, J. A., Harper, J. W., Eisenman, R. N., & Clurman, B. E. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0402770101 · Cited by 941
Patra, K. C., Wang, Q., Bhaskar, P. T., Miller, L., Wang, Z., Wheaton, W., Chandel, N., Laakso, M., Muller, W. J., Allen, E. L., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.06.014 · Cited by 853
Wolf, A., Agnihotri, S., Micallef, J., Mukherjee, J., Sabha, N., Cairns, R., Hawkins, C., & Guha, A. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20101470 · Cited by 789
Mitochondrial Binding of Hexokinase II Inhibits Bax-induced Cytochrome c Release and Apoptosis
Pastorino, J. G., Shulga, N., & Hoek, J. B. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m109950200 · Cited by 713
Lactate dehydrogenase A: A key player in carcinogenesis and potential target in cancer therapy
Feng, Y., Xiong, Y., Qiao, T., Li, X., Jia, L., & Han, Y. (2018) · Cancer Medicine · doi:10.1002/cam4.1820 · Cited by 705
Emerging roles and the regulation of aerobic glycolysis in hepatocellular carcinoma
Feng, J., Li, J., Wu, L., Yu, Q., Ji, J., Wu, J., Dai, W., & Guo, C. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01629-4 · Cited by 699
The pentose phosphate pathway in health and disease
TeSlaa, T., Ralser, M., Fan, J., & Rabinowitz, J. D. (2023) · Nature Metabolism · doi:10.1038/s42255-023-00863-2 · Cited by 650
Metabolic dysregulation and emerging therapeutical targets for hepatocellular carcinoma
Du, D., Liu, C., Qin, M., Zhang, X., Xi, T., Yuan, S., Hao, H., & Xiong, J. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.09.019 · Cited by 643
Majewski, N., Nogueira, V., Bhaskar, P., Coy, P. E., Skeen, J. E., Gottlob, K., Chandel, N. S., Thompson, C. B., Robey, R. B., & Hay, N. (2004) · Molecular Cell · doi:10.1016/j.molcel.2004.11.014 · Cited by 633
A Pan-Cancer Proteogenomic Atlas of PI3K/AKT/mTOR Pathway Alterations
Zhang, Y., Kwok-Shing Ng, P., Kucherlapati, M., Chen, F., Liu, Y., Tsang, Y. H., de Velasco, G., Jeong, K. J., Akbani, R., Hadjipanayis, A., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.04.013 · Cited by 626 · cited 1×
“Common tumorigenic changes include: activating mutations in PIK3CA, the p110 catalytic subunit of PI3K1; deletion/loss of function in PTEN; amplification/activation of PI3K upstream regulators, particularly receptor tyrosine kinases (RTKs); amplification/gain of function in Akt [7].”
BackgroundHypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer
Thomas, G. V., Tran, C., Mellinghoff, I. K., Welsbie, D. S., Chan, E., Fueger, B., Czernin, J., & Sawyers, C. L. (2006) · Nature Medicine · doi:10.1038/nm1337 · Cited by 604
Sun, Q., Chen, X., Ma, J., Peng, H., Wang, F., Zha, X., Wang, Y., Jing, Y., Yang, H., Chen, R., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1014769108 · Cited by 586
Akt-dependent metabolic reprogramming regulates tumor cell histone acetylation
Lee, J. V., Carrer, A., Shah, S., Snyder, N. W., Wei, S., Venneti, S., Worth, A. J., Yuan, Z.-F., Lim, H.-W., Liu, S., et al. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.06.004 · Cited by 563
Glucose transporters in cancer – from tumor cells to the tumor microenvironment
Ancey, P., Contat, C., & Meylan, E. (2018) · The FEBS Journal · doi:10.1111/febs.14577 · Cited by 514
Shikonin and its analogs inhibit cancer cell glycolysis by targeting tumor pyruvate kinase-M2
Chen, J., Xie, J., Jiang, Z., Wang, B., Wang, Y., & Hu, X. (2011) · Oncogene · doi:10.1038/onc.2011.137 · Cited by 512
Pyruvate Kinase M2 and Cancer: The Role of PKM2 in Promoting Tumorigenesis
Zahra, K., Dey, T., Ashish, Mishra, S. P., & Pandey, U. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00159 · Cited by 501
Cancer Cell Metabolism in Hypoxia: Role of HIF-1 as Key Regulator and Therapeutic Target
Infantino, V., Santarsiero, A., Convertini, P., Todisco, S., & Iacobazzi, V. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115703 · Cited by 499
Phosphorylation by Glycogen Synthase Kinase-3 Controls c-Myc Proteolysis and Subnuclear Localization
Gregory, M. A., Qi, Y., & Hann, S. R. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m310722200 · Cited by 475
Porstmann, T., Griffiths, B., Chung, Y.-L., Delpuech, O., Griffiths, J. R., Downward, J., & Schulze, A. (2005) · Oncogene · doi:10.1038/sj.onc.1208802 · Cited by 455
Phosphoinositide 3-Kinase/Akt Signaling and Redox Metabolism in Cancer
Koundouros, N., & Poulogiannis, G. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00160 · Cited by 415
Metabolic reprogramming of cancer-associated fibroblasts and its effect on cancer cell reprogramming
Li, Z., Sun, C., & Qin, Z. (2021) · Theranostics · doi:10.7150/thno.62378 · Cited by 390
Comparative Metabolic Flux Profiling of Melanoma Cell Lines
Scott, D. A., Richardson, A. D., Filipp, F. V., Knutzen, C. A., Chiang, G. G., Ronai, Z. A., Osterman, A. L., & Smith, J. W. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.282046 · Cited by 328
Atsumi, T., Chesney, J. A., Metz, C. N., Leng, L., Donnelly, S. C., Makita, Z., Mitchell, R., & Bucala, R. (2002) · PubMed · Cited by 323
Targeting SREBP-1-driven Lipid Metabolism to Treat Cancer
Guo, D., Bell, E., Mischel, P., & Chakravarti, A. (2014) · Current Pharmaceutical Design · doi:10.2174/13816128113199990486 · Cited by 323
Acetyl-CoA Metabolism Supports Multistep Pancreatic Tumorigenesis
Carrer, A., Trefely, S., Zhao, S., Campbell, S. L., Norgard, R. J., Schultz, K. C., Sidoli, S., Parris, J. L. D., Affronti, H. C., Sivanand, S., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0567 · Cited by 313
Chiara, F., Castellaro, D., Marin, O., Petronilli, V., Brusilow, W. S., Juhaszova, M., Sollott, S. J., Forte, M., Bernardi, P., & Rasola, A. (2008) · PLoS ONE · doi:10.1371/journal.pone.0001852 · Cited by 290
Majewski, N., Nogueira, V., Robey, R. B., & Hay, N. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.2.730-740.2004 · Cited by 289
Wang, L., Xiong, H., Wu, F., Zhang, Y., Wang, J., Zhao, L., Guo, X., Chang, L.-J., Zhang, Y., You, M. J., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.07.053 · Cited by 288
Oncogenic PI3K and K-Ras stimulate de novo lipid synthesis through mTORC1 and SREBP
Ricoult, S. J. H., Yecies, J. L., Ben-Sahra, I., & Manning, B. D. (2016) · Oncogene · doi:10.1038/onc.2015.179 · Cited by 281
Cancer Cells Tune the Signaling Pathways to Empower de Novo Synthesis of Nucleotides
Villa, E., Ali, E., Sahu, U., & Ben-Sahra, I. (2019) · Cancers · doi:10.3390/cancers11050688 · Cited by 281
PI3K Inhibitors in Cancer: Clinical Implications and Adverse Effects
Mishra, R., Patel, H., Alanazi, S., Kilroy, M. K., & Garrett, J. T. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073464 · Cited by 281
Cunningham, J. T., Moreno, M. V., Lodi, A., Ronen, S. M., & Ruggero, D. (2014) · Cell · doi:10.1016/j.cell.2014.03.052 · Cited by 260
Direct role of nucleotide metabolism in C-MYC-dependent proliferation of melanoma cells
Mannava, S., Grachtchouk, V., Wheeler, L. J., Im, M., Zhuang, D., Slavina, E. G., Mathews, C. K., Shewach, D. S., & Nikiforov, M. A. (2008) · Cell Cycle · doi:10.4161/cc.6390 · Cited by 257 · cited 1×
“Of note, Akt can also upregulate the PPP by controlling the activity of other enzymes, either directly – as in the case of transketolase (TKT) [134,135] – or indirectly – by stimulating the MYC-related transcription and translation of phosphoribosyl pyrophosphate (PRPP) synthase 2 (PRPS2) [136,137].”
BackgroundGranchi, C. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.09.001 · Cited by 245
Mitochondrial localization of TIGAR under hypoxia stimulates HK2 and lowers ROS and cell death
Cheung, E. C., Ludwig, R. L., & Vousden, K. H. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1206530109 · Cited by 244
Hexokinase 2 in Cancer: A Prima Donna Playing Multiple Characters
Ciscato, F., Ferrone, L., Masgras, I., Laquatra, C., & Rasola, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094716 · Cited by 239
Identification of small molecule inhibitors of pyruvate kinase M2
Vander Heiden, M. G., Christofk, H. R., Schuman, E., Subtelny, A. O., Sharfi, H., Harlow, E. E., Xian, J., & Cantley, L. C. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2009.12.003 · Cited by 237
The Warburg effect: Evolving interpretations of an established concept
Chen, X., Qian, Y., & Wu, S. (2015) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2014.08.027 · Cited by 229
Unlocking the Potential of HK2 in Cancer Metabolism and Therapeutics
Garcia, S. N., Guedes, R. C., & Marques, M. M. (2020) · Current Medicinal Chemistry · doi:10.2174/0929867326666181213092652 · Cited by 227
Myc‐induced proliferation and transformation require Akt‐mediated phosphorylation of FoxO proteins
Bouchard, C., Marquardt, J., Brás, A., Medema, R. H., & Eilers, M. (2004) · The EMBO Journal · doi:10.1038/sj.emboj.7600279 · Cited by 210
Gouw, A. M., Margulis, K., Liu, N. S., Raman, S. J., Mancuso, A., Toal, G. G., Tong, L., Mosley, A., Hsieh, A. L., Sullivan, D. K., et al. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.07.012 · Cited by 200
Anderson, M., Marayati, R., Moffitt, R., & Yeh, J. J. (2017) · Oncotarget · doi:10.18632/oncotarget.9760 · Cited by 193
Yi, M., Ban, Y., Tan, Y., Xiong, W., Li, G., & Xiang, B. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2018.11.013 · Cited by 187
Translational induction of the c-myc oncogene via activation of the FRAP/TOR signalling pathway
West, M. J., Stoneley, M., & Willis, A. E. (1998) · Oncogene · doi:10.1038/sj.onc.1201990 · Cited by 183
Glucose Metabolism Heterogeneity in Human and Mouse Malignant Glioma Cell Lines
Griguer, C. E., Oliva, C. R., & Gillespie, G. Y. (2005) · Journal of Neuro-Oncology · doi:10.1007/s11060-004-6404-6 · Cited by 178
ATP Citrate Lyase (ACLY): A Promising Target for Cancer Prevention and Treatment
Khwairakpam, A., Shyamananda, M., Sailo, B., Rathnakaram, S., Padmavathi, G., Kotoky, J., & Kunnumakkara, A. (2015) · Current Drug Targets · doi:10.2174/1389450115666141224125117 · Cited by 173
Kotowski, K. W., Rosik, J., Machaj, F., Supplitt, S., Wiczew, D., Jabłońska, K., Wiecheć, E., Ghavami, S., & Dzięgiel, P. (2021) · Cancers · doi:10.3390/cancers13040909 · Cited by 156
Shikonin Inhibits Tumor Growth in Mice by Suppressing Pyruvate Kinase M2-mediated Aerobic Glycolysis
Zhao, X., Zhu, Y., Hu, J., Jiang, L., Li, L., Jia, S., & Zen, K. (2018) · Scientific Reports · doi:10.1038/s41598-018-31615-y · Cited by 154
Direct stimulation of NADP + synthesis through Akt-mediated phosphorylation of NAD kinase
Hoxhaj, G., Ben‐Sahra, I., Lockwood, S. E., Timson, R. C., Byles, V., Henning, G. T., Gao, P., Selfors, L. M., Asara, J. M., & Manning, B. D. (2019) · Science · doi:10.1126/science.aau3903 · Cited by 152
Lactate oxidase nanocapsules boost T cell immunity and efficacy of cancer immunotherapy
Cao, Z., Xu, D., Harding, J., Chen, W., Liu, X., Wang, Z., Wang, L., Qi, T., Chen, S., Guo, X., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.add2712 · Cited by 146
Khezri, M. R., Jafari, R., Yousefi, K., & Zolbanin, N. M. (2022) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2022.104787 · Cited by 142
Zhang, X., Zhang, M., Cong, Q., Zhang, M., Zhang, M., Lu, Y., & Xu, C. (2017) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2017.12.010 · Cited by 141
Yang, T., Ren, C., Qiao, P., Han, X., Wang, L., Lv, S., Sun, Y., Liu, Z., Du, Y., & Yu, Z. (2018) · Oncogene · doi:10.1038/s41388-018-0386-x · Cited by 140
Akt: a key transducer in cancer
Tsai, P., Lai, Y., Manne, R., Tsai, Y.-S., Sarbassov, D. D., & Lin, H. (2022) · Journal of Biomedical Science · doi:10.1186/s12929-022-00860-9 · Cited by 140
‘Reverse Warburg effect’ of cancer‑associated fibroblasts (Review)
Liang, L., Li, W., Li, X., Jin, X., Liao, Q., Li, Y., & Zhou, Y. (2022) · International Journal of Oncology · doi:10.3892/ijo.2022.5357 · Cited by 137
LDHA is necessary for the tumorigenicity of esophageal squamous cell carcinoma
Yao, F., Zhao, T., Zhong, C., Zhu, J. J., & Zhao, H. (2012) · Tumor Biology · doi:10.1007/s13277-012-0506-0 · Cited by 135
Ciscato, F., Filadi, R., Masgras, I., Pizzi, M., Marin, O., Damiano, N., Pizzo, P., Gori, A., Frezzato, F., Chiara, F., et al. (2020) · EMBO Reports · doi:10.15252/embr.201949117 · Cited by 133
Pyruvate Kinase M2 Activates mTORC1 by Phosphorylating AKT1S1
He, C.-L., Bian, Y., Xue, Y., Liu, Z., Zhou, K.-Q., Yao, C.-F., Lin, Y., Zou, H.-F., Luo, F.-X., Qu, Y.-Y., et al. (2016) · Scientific Reports · doi:10.1038/srep21524 · Cited by 132
Diedrich, J. D., Rajagurubandara, E. N., Herroon, M. K., Mahapatra, G., Hüttemann, M., & Podgorski, I. (2016) · Oncotarget · doi:10.18632/oncotarget.11712 · Cited by 126
Regulatory Role of Glycogen Synthase Kinase 3 for Transcriptional Activity of ADD1/SREBP1c
Kim, K. H., Song, M. J., Yoo, E. J., Choe, S. S., Park, S. D., & Kim, J. B. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m405522200 · Cited by 122
Wiegering, A., Uthe, F. W., Jamieson, T. J., Ruoss, Y., Hüttenrauch, M., Küspert, M., Pfann, C., Nixon, C., Herold, S., Walz, S., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-1040 · Cited by 121
Wang, C., Jiang, J., Ji, J., Cai, Q., Chen, X., Yu, Y., Zhu, Z., & Zhang, J. (2017) · Scientific Reports · doi:10.1038/s41598-017-03031-1 · Cited by 118
Ning, X., Qi, H., Li, R., Li, Y., Jin, Y., McNutt, M. A., Liu, J., & Yin, Y. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.06.064 · Cited by 116
Hong, S. Y., Yu, F., Luo, Y., & Hagen, T. (2016) · Cellular Signalling · doi:10.1016/j.cellsig.2016.01.011 · Cited by 113
Saha, A., Connelly, S., Jiang, J., Zhuang, S., Amador, D., Phan, T., Pilz, R. B., & Boss, G. R. (2014) · Molecular Cell · doi:10.1016/j.molcel.2014.05.028 · Cited by 106
SIRT3 Enhances Glycolysis and Proliferation in SIRT3-Expressing Gastric Cancer Cells
Cui, Y., Qin, L., Wu, J., Qu, X., Hou, C., Sun, W., Li, S., Vaughan, A. T., Li, J. J., & Liu, J. (2015) · PLoS ONE · doi:10.1371/journal.pone.0129834 · Cited by 102
Minchenko, О. H., Ochiai, A., Opentanova, I., Ogura, T., Minchenko, D. O., Caro, J., Комісаренко, С. В., & Esumi, H. (2005) · Biochimie · doi:10.1016/j.biochi.2005.04.007 · Cited by 102
Lee, J., & Ridgway, N. D. (2019) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2019.03.010 · Cited by 100
Molecular Crosstalk Between MYC and HIF in Cancer
Li, Y., Sun, X., Qian, D. Z., & Dai, M. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.590576 · Cited by 98
PTEN/Akt Signaling Controls Mitochondrial Respiratory Capacity through 4E-BP1
Goo, C. K., Lim, H. Y., Ho, Q. S., Too, H.-P., Clement, M.-V., & Wong, K. P. (2012) · PLoS ONE · doi:10.1371/journal.pone.0045806 · Cited by 97
Mechanisms of regulation of PFKFB expression in pancreatic and gastric cancer cells
Minchenko, О. H., Tsuchihara, K., Minchenko, D. O., Bikfalvi, A., & Esumi, H. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i38.13705 · Cited by 97
Hexokinases in cancer and other pathologies
Guo, D. S., Meng, Y., Jiang, X., & Lu, Z. (2023) · Cell Insight · doi:10.1016/j.cellin.2023.100077 · Cited by 96
Phosphoinositide 3-kinase inhibitors induce DNA damage through nucleoside depletion
Juvekar, A., Hu, H., Yadegarynia, S., Lyssiotis, C. A., Ullas, S., Lien, E. C., Bellinger, G., Son, J., Hok, R. C., Seth, P., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1522223113 · Cited by 93
Interaction between adipose tissue and cancer cells: role for cancer progression
Dumas, J., & Brisson, L. (2020) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09934-2 · Cited by 93
Fantin, V. R., St‐Pierre, J., & Leder, P. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.07.011 · Cited by 92
Chen, C., Liu, W.-R., Zhang, B., Zhang, L.-M., Li, C., Liu, C., Zhang, H., Huo, Y., Ma, Y.-C., Tian, P., et al. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.05.009 · Cited by 91
Yang, T., Ren, C., Qiao, P., Han, X., Wang, L., Lv, S., Sun, Y., Liu, Z., Du, Y., & Yu, Z. (2019) · Oncogene · doi:10.1038/s41388-019-0982-4 · Cited by 90
Novellasdemunt, L., Tato, I., Navarro‐Sabaté, À., Ruiz‐Meana, M., Méndez‐Lucas, A., Perales, J. C., García‐Dorado, D., Ventura, F., Bartrons, R., & Rosa, J. L. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.455998 · Cited by 86
PHLPP regulates hexokinase 2-dependent glucose metabolism in colon cancer cells
Xiong, X., Wen, Y., Mitov, M. I., Oaks, M. C., Miyamoto, S., & Gao, T. (2017) · Cell Death Discovery · doi:10.1038/cddiscovery.2016.103 · Cited by 83
PFKFB3 is involved in breast cancer proliferation, migration, invasion and angiogenesis
Peng, F., Li, Q., Sun, J.-Y., Luo, Y., Chen, M., & Bao, Y. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4257 · Cited by 80
Deoxyribonucleotide Triphosphate Metabolism in Cancer and Metabolic Disease
Buj, R., & Aird, K. M. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00177 · Cited by 78
Targeting hexokinase 2 enhances response to radio-chemotherapy in glioblastoma
Vartanian, A., Agnihotri, S., Wilson, M. R., Burrell, K. E., Tonge, P. D., Alamsahebpour, A., Jalali, S., Taccone, M. S., Mansouri, S., Golbourn, B. J., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11680 · Cited by 76
Ye, G., Qin, Y. W., Wang, S., Pan, D., Xu, S., Wu, C., Wang, X., Wang, J., Ye, H., & Shen, H. (2019) · Cancer Biology & Therapy · doi:10.1080/15384047.2018.1564558 · Cited by 75
PFKFB3 blockade inhibits hepatocellular carcinoma growth by impairing DNA repair through AKT
Shi, W.-K., Zhu, X.-D., Wang, C.-H., Zhang, Y.-Y., Cai, H., Li, X., Cao, M.-Q., Zhang, S.-Z., Li, K.-S., & Sun, H. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0435-y · Cited by 74
Vazquez, A., & Oltvai, Z. N. (2011) · PLoS ONE · doi:10.1371/journal.pone.0019538 · Cited by 70 · cited 1×
“Finally, it has been recently postulated that the Warburg effect might result from molecular crowding, a common limitation to overall metabolism in rapidly proliferating cells [12].”
BackgroundQi, C., Huang, M., Zou, Y., Yang, R., Jiang, Y., Sheng, J., Kong, Y., Tao, Z., Feng, H., Hua, Q., et al. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02191-3 · Cited by 70
Choi, H., Yeo, M., Kang, Y., Kim, H. J., Park, S. G., Jang, E., Park, S. H., Kim, E., & Kang, S. (2023) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01762-6 · Cited by 68
Cerniglia, G. J., Dey, S., Gallagher‐Colombo, S. M., Daurio, N. A., Tuttle, S. W., Busch, T. M., Lin, A., Sun, R. C., Esipova, T. V., Vinogradov, S. A., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0888 · Cited by 67
mTOR up-regulation of PFKFB3 is essential for acute myeloid leukemia cell survival
Feng, Y., & Wu, L.-S. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.01.031 · Cited by 65
Respiratory competent mitochondria in human ovarian and peritoneal cancer
Lim, H. Y., Ho, Q. S., Low, J. J. H., Choolani, M. A., & Wong, K. P. (2011) · Mitochondrion · doi:10.1016/j.mito.2010.12.015 · Cited by 64
Coleman, N., Moyers, J. T., Harbery, A., Vivanco, I., & Yap, T. A. (2021) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s305068 · Cited by 64
Pantic, B., Trevisan, E., Citta, A., Rigobello, M. P., Marin, O., Bernardi, P., Salvatori, S., & Rasola, A. (2013) · Cell Death and Disease · doi:10.1038/cddis.2013.385 · Cited by 63
Matsubara, M., & Bissell, M. J. (2016) · Oncotarget · doi:10.18632/oncotarget.9395 · Cited by 63
Lactate dehydrogenase A promotes the invasion and proliferation of pituitary adenoma
An, J., Zhang, Y., He, J., Zang, Z., Zhou, Z., Pei, X., Zheng, X., Zhang, W., Yang, H., & Li, S. (2017) · Scientific Reports · doi:10.1038/s41598-017-04366-5 · Cited by 61
Zheng, B., Li, G., Zeng, L., Liu, F., & Huang, Q. (2018) · Cellular Signalling · doi:10.1016/j.cellsig.2018.01.021 · Cited by 61
Jin, F., Zhou, S., Fan, J., & Yan, S. (2014) · Molecular Medicine Reports · doi:10.3892/mmr.2014.2888 · Cited by 55
AKT-induced PKM2 phosphorylation signals for IGF-1-stimulated cancer cell growth
Park, Y. S., Kim, D. J., Koo, H., Jang, S. H., You, Y.-M., Cho, J. H., Yang, S., Yu, E. S., Jung, Y., Lee, D. C., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10179 · Cited by 55
PIK3CA mutant tumors depend on oxoglutarate dehydrogenase
Ilić, N., Birsoy, K., Aguirre, A. J., Kory, N., Pacold, M. E., Singh, S., Moody, S. E., DeAngelo, J. D., Spardy, N. A., Freinkman, E., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1617922114 · Cited by 55
Nogueira, V., Patra, K. C., & Hay, N. (2018) · eLife · doi:10.7554/elife.32213 · Cited by 54
Fan, K., Fan, Z., He, C., Huang, Q., Yang, C., Jin, K., Luo, G., Yu, X., & Liu, C. (2019) · Cancer Medicine · doi:10.1002/cam4.2463 · Cited by 53
The multifaceted roles of mitochondria at the crossroads of cell life and death in cancer
Fontana, F., & Limonta, P. (2021) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2021.09.024 · Cited by 53
Self-citationZhang, K., Zhang, M., Jiang, H., Liu, F., Liu, H., & Yang, L. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.06.009 · Cited by 52
The Roles of HK2 on Tumorigenesis of Cervical Cancer
Liu, C., Wang, X., & Zhang, Y. (2019) · Technology in Cancer Research & Treatment · doi:10.1177/1533033819871306 · Cited by 52
Luan, Y., Zhang, W., Xie, J., & Mao, J. (2020) · Clinical & Translational Oncology · doi:10.1007/s12094-020-02409-4 · Cited by 51
LDHA as a regulator of T cell fate and its mechanisms in disease
Dai, M., Wang, L., Yang, J., Chen, J., Dou, X., Chen, R., Ge, Y., & Lin, Y. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.114164 · Cited by 51
Wu, J., Hu, L., Chen, M., Cao, W., Chen, H., & He, T. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s106508 · Cited by 49
Ning, X., Qi, H., Li, R., Jin, Y., McNutt, M. A., & Yin, Y. (2017) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2017.1404591 · Cited by 47
Gu, J. J., Singh, A., Xue, K., Mavis, C. K., Barth, M. J., Yanamadala, V., Lenz, P., Grau, M., Lenz, G., Czuczman, M. S., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.23425 · Cited by 47
Han, J., Meng, Q., Xi, Q., Wang, H., & Wu, G. (2016) · Cancer Biomarkers · doi:10.3233/cbm-160143 · Cited by 46
Zhang, X., Ai, Z., Chen, J., Yi, J., Liu, Z., Zhao, H.-S., & Wei, H. (2017) · Molecular Medicine Reports · doi:10.3892/mmr.2017.6189 · Cited by 42
Yoo, J., Yu, S. J., Na, J., Kim, K., Cho, Y. Y., Lee, Y. B., Cho, E. J., Lee, J., Kim, Y. J., Youn, H., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20061292 · Cited by 42
Role of the Sterol Regulatory Element Binding Protein Pathway in Tumorigenesis
Jiang, T., Zhang, G., & Lou, Z. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01788 · Cited by 42
Direct and indirect targeting of MYC to treat acute myeloid leukemia
Brondfield, S., Umesh, S., Corella, A. N., Zuber, J. A., Rappaport, A., Gaillard, C. M., Lowe, S. W., Goga, A., & Kogan, S. C. (2015) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-015-2766-z · Cited by 41
Fructose 2,6-bisphosphate metabolism in Ehrlich ascites tumour cells
Nissler, K., Petermann, H., Wenz, I., & Brox, D. H. (1995) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/bf01213320 · Cited by 41
Fontana, F., Raimondi, M., Marzagalli, M., Audano, M., Beretta, G., Procacci, P., Sartori, P., Mitro, N., & Limonta, P. (2020) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2020.07.009 · Cited by 41
Self-citationUnraveling the Peculiar Features of Mitochondrial Metabolism and Dynamics in Prostate Cancer
Fontana, F., Anselmi, M., & Limonta, P. (2023) · Cancers · doi:10.3390/cancers15041192 · Cited by 40
Self-citationWang, Y., Pan, S., He, X., Wang, Y., Huang, H., Chen, J., Zhang, Y., Zhang, Z., & Qin, X. (2021) · OncoTargets and Therapy · doi:10.2147/ott.s284211 · Cited by 39
Huang, X., Liu, M., Sun, H., Wang, F., Xie, X., Chen, X. '., Su, J., He, Y., Dai, Y., Wu, H., et al. (2015) · Europe PMC (PubMed Central) · Cited by 38
Liu, Y., Wu, K., Shi, L., Xiang, F., Tao, K., & Wang, G. (2016) · PLoS ONE · doi:10.1371/journal.pone.0166230 · Cited by 38
Patra, K. C., Wang, Q., Bhaskar, P. T., Miller, L. L., Wang, Z., Wheaton, W. W., Chandel, N. S., Laakso, M., Muller, W. J., Allen, E. L., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.08.029 · Cited by 36
Fontana, F., Anselmi, M., Carollo, E., Sartori, P., Procacci, P., Carter, D., & Limonta, P. (2022) · Cells · doi:10.3390/cells11152388 · Cited by 36
Self-citationDeWaal, D. C., Nogueira, V., Terry, A. R., Patra, K. C., Jeon, S., Guzman, G., Au, J., Long, C. P., Antoniewicz, M. R., & Hay, N. (2018) · Nature Communications · doi:10.1038/s41467-018-04182-z · Cited by 33
Lu, H., Chen, S., You, Z., Xie, C., Huang, S., & Hu, X. (2020) · Development Growth & Differentiation · doi:10.1111/dgd.12645 · Cited by 33
Natural products targeting glycolytic signaling pathways-an updated review on anti-cancer therapy
Cui, Y., Li, C., Sang, F., Cao, W., Qin, Z., & Zhang, P. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1035882 · Cited by 33
Dermit, M., Casado, P., Rajeeve, V., Wilkes, E. H., Foxler, D. E., Campbell, H., Critchlow, S. E., Sharp, T. V., Gribben, J. G., Unwin, R. J., et al. (2016) · Oncogene · doi:10.1038/onc.2016.435 · Cited by 32
PHLPPing the Script: Emerging Roles of PHLPP Phosphatases in Cell Signaling
Baffi, T. R., Cohen‐Katsenelson, K., & Newton, A. C. (2020) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-031820-122108 · Cited by 32
Prolactin Inhibits Activity of Pyruvate Kinase M2 to Stimulate Cell Proliferation
Varghese, B., Swaminathan, G., Plotnikov, A., Tzimas, C., Yang, N., Rui, H., & Fuchs, S. Y. (2010) · Molecular Endocrinology · doi:10.1210/me.2010-0219 · Cited by 27
Expression of metabolically targeted biomarkers in endometrial carcinoma
Wahl, H. N., Daudi, S., Kshirsagar, M. P., Griffith, K. A., Tan, L., Rhode, J. M., & Liu, J. R. (2009) · Gynecologic Oncology · doi:10.1016/j.ygyno.2009.10.040 · Cited by 25
Safaroghli‐Azar, A., Bashash, D., Kazemi, A., Pourbagheri‐Sigaroodi, A., & Momeny, M. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.10.036 · Cited by 25
The impairment of respiration by glycolysis in the Lewis lung carcinoma
Miralpeix, M., Azcón‐Bieto, J., Bartrons, R., & Argilés, J. M. A. (1990) · Cancer Letters · doi:10.1016/0304-3835(90)90261-u · Cited by 23
Cirone, M., & D’Orazi, G. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms24010595 · Cited by 22
Fontana, F., Anselmi, M., & Limonta, P. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23095269 · Cited by 21
Self-citationChen, Q., Li, L., Liu, X., Feng, Q., Zhang, Y., Zheng, P., & Cui, N. (2021) · Cancer Cell International · doi:10.1186/s12935-021-02312-0 · Cited by 20
Lin, C., Chen, H., Han, R., Li, L., Lu, C., Hao, S., Wang, Y., & He, Y. (2021) · Thoracic Cancer · doi:10.1111/1759-7714.14184 · Cited by 20
Li, Y., He, Z., Liu, Q., Zhou, K., Shi, Y., Yao, X., Zhang, X., Kung, H., Ping, Y., & Bian, X. (2018) · Journal of Cancer · doi:10.7150/jca.20869 · Cited by 18
Long, W., Gong, X., Yang, Y., & Yang, K. (2020) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2020.05.035 · Cited by 17
Jin, F., Bao, Y., Zhou, S., Luo, X., Yao, H., He, J., & Wang, Q. (2012) · Oncology Letters · doi:10.3892/ol.2012.895 · Cited by 16
Liu, X., Liu, H., Zeng, L., & Lv, Y. (2022) · PeerJ · doi:10.7717/peerj.14052 · Cited by 16
Zhang, Q., Zhang, J., Yao, A., Tian, X., Han, Z., Yuan, Y., Tao, K., & Yang, X. (2022) · Cell Biology International · doi:10.1002/cbin.11950 · Cited by 14
PFKFB4 interacts with ICMT and activates RAS/AKT signaling-dependent cell migration in melanoma
Sittewelle, M., Kappès, V., Zhou, C., Lécuyer, D., & Monsoro-Burq, A. H. (2022) · Life Science Alliance · doi:10.26508/lsa.202201377 · Cited by 13
Identification of novel inhibitors of GLUT1 by virtual screening and cell-based assays
Chen, X., Zhao, Y., Lyu, S., Gao, G., Gao, Y., Qi, Y., & Du, J. (2021) · Investigational New Drugs · doi:10.1007/s10637-021-01109-2 · Cited by 10
Extracellular Hsp90α Supports the ePKM2-GRP78-AKT Axis to Promote Tumor Metastasis
Zhang, S., Wang, C., Ju, J., & Wang, C. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.906080 · Cited by 5
Cited by
Altered metabolism in cancer: insights into energy pathways and therapeutic targets
Tufail, M., Jiang, C.-H., & Li, N. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02119-3 · Cited by 534
Metabolic reprogramming: The driving force behind cancer drug resistance
El-Sehrawy, A. A. M. A., Hsu, C.-Y., Alkhathami, A. G., Chandra, M., Basunduwah, T. S., Malathi, H., Senapati, J. N., Gautam, A., Kadhem, M., & Yasin, H. A. (2025) · Seminars in Oncology · doi:10.1016/j.seminoncol.2025.152392 · Cited by 11
Metadata
- Authors
- Fontana, F., Giannitti, G., Marchesi, S., & Limonta, P.
- Venue
- International Journal of Biological Sciences
- Publisher
- Ivyspring International Publisher
- Published
- 2024
- Volume
- 20
- Issue
- 8
- Pages
- 3113-3125
- ISSN
- 1449-2288 (ISSN-L)
- OpenAlex
- W4399127042
- Cited by
- 280
- References
- 170
- FWCI
- 42.84
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.